Global Tamoxifen Market
Tamoxifen is a type of selective estrogen receptor modulator (SERM) indicated for the treatment of women at a high risk of breast cancer. Since its approval in 1998, tamoxifen has been used to treat millions of patients diagnosed with hormone receptor positive, as well as early-stage breast cancer, usually post-surgery to reduce the chances of recurrence. It is one of the first choices for the treatment of premenopausal women. For the record, tamoxifen is the generic name for Nolvadex. It has an off-label usage for the treatment of infertility, gynecomastia, retroperitoneal fibrosis, and idiopathic sclerosing mesenteritis.
The main pharmacological function of Tamoxifen is to block the growth-promoting effects of estrogens on breast cancer. In bone cells, selective estrogen modulators interact with receptors the way estrogen does and strengthens bones. Tamoxifen is available in various forms, such as powder, capsules, oral solutions, and tablets.
𝐓𝐨 𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐏𝐃𝐅 𝐁𝐫𝐨𝐜𝐡𝐮𝐫𝐞 𝐇𝐞𝐫𝐞 @https://www.coherentmarketinsights.com/insight/request-pdf/1801
Global Tamoxifen Market Dynamics
Since tamoxifen is a generic molecule, growth of the global tamoxifen market has declined with increased competition. However, the emergence of combination therapies and additional therapeutic indications for tamoxifen is expected to fuel the global market growth. For instance, 2018 Novartis received breakthrough therapy designation for Kisqali by FDA in Phase 3. Designation was based on the successful phase 3 MONALEESA-7 trials, which demonstrated significant prolonged-free survival (PFS) of Kisqali + tamoxifen (or an aromatase inhibitor).
Moreover, increased investments from government and non-government organizations intended to discover the additional therapeutic applications of tamoxifen, are projected to propel the global market growth. For instance, in 2017, Duchenne UK, E-Rare, Duchenne Parent Project, and Monaco Association jointly contributed up to US$ 766,338 for a clinical trial that was aimed at studying the effects of tamoxifen on muscular dystrophy.
However, in 2017, a survey conducted by the European Cancer Congress discovered that the cost of tamoxifen, despite being generic, increased around ten times over 2011-2016. The research found that the cost of the drug was 20 times the price in India. Such disparity in prices, with no adequate reimbursement deters acceptance for the drug. Furthermore, adverse effects of tamoxifen therapy such as anxiety, vaginal discharge, and painful urination, is expected to hamper the global tamoxifen market growth. Furthermore, rising prevalence of breast cancer among women, in both developed and evolving economies, is a major aspect fueling the growth of the global tamoxifen market.
𝐓𝐨 𝐆𝐞𝐭 𝐦𝐨𝐫𝐞 𝐢𝐧𝐟𝐨𝐫𝐦𝐚𝐭𝐢𝐨𝐧 𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐟𝐨𝐫 𝐒𝐚𝐦𝐩𝐥𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 𝐚𝐭 – https://www.coherentmarketinsights.com/insight/request-sample/1801
Global Tamoxifen Market – Regional Insights
The North America tamoxifen market holds a highly dominant position in the global market, owing to high prices of the drug used in treating breast cancer. According to GoodRx Inc.’s 2018 pricing detail, 30 tablets of tamoxifen 20mg cost around US$ 65.71 on an average. In addition, rising prevalence of breast cancer has propelled the tamoxifen market growth in this region.
Asia Pacific is expected to witness considerable growth in the global tamoxifen market over the forecast period, owing to the increasing vulnerability among people to various chronic diseases, and growing number of healthcare initiatives. According to an article published in the Lancet Oncology 2014, the incidence rate of breast cancer in the region is expected to rise from less than 60 cases per 100,000 women, aged 55 years to 69 years, to over 100 cases per 100,000 women by 2023.
Global Tamoxifen Market – Competitive Scenario
The key players operating in the global tamoxifen market include Teva Pharmaceutical Industries Ltd, AstraZeneca Plc, Aegis pharmaceuticals, Watson laboratories, Inc., Allergan Plc, Mylan N.V., and Apotex Inc.
These players are presently focusing on the adoption of various strategies, such as acquisitions and mergers, to provide advanced research products to sustain their presence in the global market. For instance, in 2018, Dare Bioscience Inc. announced a merger agreement with Pear Tree Pharmaceuticals to procure the rights to develop PT-101, as a potential treatment for vaginal and vulvar atrophy for patients suffering from hormone-receptive positive breast cancer. PT-101, for the record, is a proprietary vaginal formulation being developed by Pear Tree Pharmaceuticals.
𝐅𝐨𝐫 𝐌𝐨𝐫𝐞 𝐈𝐧𝐟𝐨𝐫𝐦𝐚𝐭𝐢𝐨𝐧 𝐨𝐫 𝐐𝐮𝐞𝐫𝐲 𝐨𝐫 𝐂𝐮𝐬𝐭𝐨𝐦𝐢𝐳𝐚𝐭𝐢𝐨𝐧 𝐛𝐞𝐟𝐨𝐫𝐞 𝐁𝐮𝐲𝐢𝐧𝐠, 𝐕𝐢𝐬𝐢𝐭 𝐚𝐭 –https://www.coherentmarketinsights.com/insight/talk-to-analyst/1801
Market Taxonomy
On the basis of dosage form:
• Powder
• Capsule
• Oral Solution
• Tablet
Based on indication:
• Breast Cancer
• Others
By region:
• North America
• Latin America
• Europe
• Asia Pacific
• Middle East
• Africa
𝐓𝐨 𝐃𝐢𝐫𝐞𝐜𝐭 𝐏𝐮𝐫𝐜𝐡𝐚𝐬𝐞 𝐭𝐡𝐢𝐬 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐑𝐞𝐩𝐨𝐫𝐭 –https://www.coherentmarketinsights.com/insight/buy-now/1801
Contact US:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: [email protected]
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
